Joel White’s Q4 CRO breakdown: strong bookings, a sell-off that didn’t match, and the disruption gap nobody is talking about

CRO bookings were up year over year and accelerating. Revenues were recovering across most major players. Delays and cancellations, after a brutal stretch through much of 2025, had moved back to something closer to normal. So why did the stocks take a beating?

That disconnect was the starting point for a forty-five-minute conversation between Joel White, founder and principal at Market Capital Consulting, and Derk Arts, CEO at Castor. Joel spent fifteen years in-house at large and mid-sized CROs before founding his own practice, where he produces the quarterly market analysis that strategy and commercial teams across the sector use to benchmark pricing and track industry performance. His Q4 recap had landed the week before — twenty to thirty pages covering every major public CRO, drug discovery platform, and biopharma equity in the sector. The session was the annotated, live version. For clinical trial technology teams navigating AI-heavy market headlines, the session addressed a question with a specific and useful answer: where is the disruption actually landing, and where is it still narrative?

The clearest finding was that the AI-pocalypse narrative hit CRO stocks not because the numbers were bad, but largely because of how some companies handled questions about it. Bookings are up year over year and accelerating. Revenues are recovering across most of the major players.

Then came the analyst questions about AI strategy. Joel described the Medpace earnings call as a turning point for sentiment. Medpace is the sector’s highest-valuation outlier, significantly smaller than an IQVIA or ICON but priced for future growth. The CEO’s response to questions about AI did not land well. The stock was, in Joel’s words, “absolutely smashed. And still to this day, very depressed.” Contrast that with IQVIA and Fortrea, whose leadership arrived prepared with structured responses that, while not resolving the underlying concern, at least prevented things from getting worse.

“When it comes to some of the doomsday scenarios, for me, I need to start seeing that growth curve somehow reverse when other things are looking good.”

Joel White, Market Capital Consulting — follow Joel’s newsletter on LinkedIn

But the session drew a clear line between two different industries. For CROs running biotech clinical trials, nothing in the Q4 earnings data yet supports the disruption thesis. Joel’s argument runs on basic economic logic: if AI lowers the cost of drug development, more drugs get developed and more trials follow. He put it directly: “I tend to believe that clinical research…is very elastic to the extent that if the cost of development goes down, there will be more things that get developed, that there will be more trials to help de-risk the developments that are already in place.” The structure of CRO contracts reinforces this. Because the overwhelming majority run on fixed-price milestones rather than hourly billing, CROs have a direct financial incentive to adopt efficiency tools regardless of whether sponsors mandate them.

For drug discovery software companies, the picture looks different. Certara, Simulations Plus, and Evotec are at or near all-time lows, with companies explicitly citing seat-based license losses as a primary driver. IQVIA agreed to acquire Charles River’s preclinical platform earlier this year at a price that drew comment in the market for how low it came in. The signal is clear: AI disruption is already visible in drug discovery software. It has not yet appeared in CRO services data.

The session also surfaced a question worth sitting with: when do efficiency gains from decentralized trial models and electronic source integration start showing up as pricing pressure on CROs? Joel’s view was measured. The technology gains are real. But the contract structures, the pace of regulatory adoption, and the gap between trial efficiency and billing models suggest the impact is years away, not quarters.

Derk put the position of regulated electronic data capture and clinical operations software on the disruption timeline directly:

“The type of software that Castor and all of our friends in the space create is going to be the last to go because it’s heavily regulated. It’s the last thing you want to vibe code, basically.”

Derk Arts, CEO at Castor

For clinical trial teams building on regulated platforms, the practical takeaway is worth sitting with. The same compliance requirements that slow AI adoption in this space also make the underlying software category more stable. Procurement cycles, validation requirements, and regulatory audit trails don’t move at the pace of a general-purpose AI tool.

The recording covers considerably more than this post captures.

Joel runs through each major public CRO company in detail, including what ICON’s simultaneous accounting investigation announcement meant for investor confidence and why the Medpace CEO’s response carried such outsized consequences. He and Derk get into the drug discovery software sector at length, covering why some of these companies are moving to bring their own drug assets in-house and what that shift might mean for the traditional service model.

There is a specific exchange about whether new trial starts built on more modern decentralized clinical trial technology stacks will look materially different, and what Joel would need to see in the numbers to genuinely change his view on the disruption timeline.

Joel followed up the session with a post-event newsletter piece that takes the CRO-as-investor angle further, including a look at how IQVIA is positioning itself in early-stage biotech funding and what that strategy signals about where large CROs think the market is heading. Worth reading alongside the recording.

Frequently asked questions

What did Q4 2025 CRO revenue and bookings data actually show?

Q4 showed bookings up year over year and accelerating across the major CROs, with revenues recovering in core direct services rather than just pass-through costs. Delays and cancellations, which had been severely elevated through much of 2025, moved into a more normalized range. ICON was the notable exception, with an internal accounting investigation announced in the same period adding company-specific pressure to broader sector sentiment.

Why did CRO stocks fall despite strong Q4 operational results?

Two factors intersected at the same time. First, a broader investor narrative about AI disrupting all software-as-a-service businesses created sector-wide pressure, catching CROs in the fallout despite their limited software revenue exposure. Second, how individual CEOs responded to AI questions on earnings calls mattered. Companies whose leadership arrived prepared with structured answers fared better than those who appeared caught off-guard. The data itself was not the problem. The narrative around it was.

How does AI disruption affect clinical operations software differently from drug discovery software?

The distinction matters a great deal. Regulated clinical operations software, including clinical trial solutions and eCOA solutions, operates under strict regulatory oversight that significantly limits the pace of AI-driven displacement. Drug discovery software companies, by contrast, are already experiencing measurable disruption in seat-based licensing, with several major players trading near all-time lows as of Q4 2025. The disruption is real. It just has not arrived uniformly across all segments of the industry.

References